Taiho Oncology (Otsuka)

Taiho Oncology, the US arm of Otsuka's Taiho based in Princeton and Tokyo, makes Inqovi, the oral decitabine and cedazuridine combination that in May 2026 became the first all-oral hypomethylating backbone for venetoclax in acute myeloid leukaemia. Cedazuridine is a cytidine deaminase inhibitor that makes oral decitabine bioavailable; Inqovi was approved for myelodysplastic syndromes and chronic myelomonocytic leukaemia in 2020 and, on 13 May 2026, with venetoclax for newly diagnosed AML in adults unfit for intensive induction on the ASCERTAIN-V trial, and the company also markets Lonsurf and futibatinib. OnCo links it to acute myeloid leukaemia and to the oral decitabine drug record. Whether an all-oral regimen changes where and how older patients with AML are treated is the open question. The FDA approval notice is linked.